Skip to main content

Novartis AG (NVS)

NYSE: NVS · IEX Real-Time Price · USD
+0.43 (0.52%)
After-hours:Sep 23, 2021 7:32 PM EDT
0.77 (0.93%)
At close: Sep 23, 4:00 PM
Market Cap204.76B
Revenue (ttm)51.56B
Net Income (ttm)8.98B
Shares Out2.24B
EPS (ttm)3.95
PE Ratio21.17
Forward PE12.27
Dividend$3.20 (3.83%)
Ex-Dividend DateMar 4, 2021
Previous Close82.80
Day's Range83.53 - 83.98
52-Week Range74.07 - 95.17
AnalystsStrong Buy
Price Target104.50 (+25.0%)
Est. Earnings DateOct 26, 2021

About NVS

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to...

IPO DateNov 18, 1991
CEOJoseph Jimenez
Stock ExchangeNYSE
Ticker SymbolNVS
Full Company Profile

Financial Performance

In 2020, Novartis's revenue was $49.90 billion, an increase of 2.51% compared to the previous year's $48.68 billion. Earnings were $8.07 billion, a decrease of -31.20%.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Novartis stock is "Strong Buy." The 12-month stock price forecast is 104.50, which is an increase of 25.04% from the latest price.

Price Target
(25.04% upside)
Analyst Consensus: Strong Buy


Novartis Adds Vision Loss Gene Therapy Program Via Arctos Acquisition

Novartis AG (NYSE: NVS) has acquired Arctos Medical, adding a preclinical optogenetics-based AAV gene therapy program and Arctos' proprietary technology to its ophthalmology portfolio.  Deal terms were ...

2 days ago - Benzinga

Novartis buys gene therapy company Arctos Medical

Novartis has bought gene therapy specialist Arctos Medical to boost its efforts finding treatments for patients with severe vision loss, the Swiss company said on Tuesday.

3 days ago - Reuters

Why Did Deutsche Bank Downgrade This Big Pharma Stock?

Deutsche Bank has downgraded Novartis AG (NYSE: NVS) to Sell from Hold with a price target of CHF 70, down from CHF 80.  Analyst Emmanuel Papadakis sees "grounds for outright caution near term" with Opt...

3 days ago - Benzinga

Novartis' Kisqali Combo Therapy Extends Survival By One Year In Breast Cancer Patients

Novartis AG (NYSE: NVS) announced results of the final overall survival (OS) analysis of Phase 3 MONALEESA-2 study, which evaluated Kisqali (ribociclib) in combination with letrozole in breast cancer pa...

3 days ago - Benzinga

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breas...

EAST HANOVER, N.J., Sept. 19, 2021 /PRNewswire/ -- Novartis today announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali ® (ribociclib)...

4 days ago - PRNewsWire

Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA...

Basel, September 17, 2021— Novartis today announced important findings from a real-world study evaluating the safety and efficacy of alpelisib for people living with PIK3CA-Related Overgrowth Spectrum (...

6 days ago - GlobeNewsWire

Novartis' Prostate Cancer Therapy Linked To Improved Quality Of Life

Novartis AG (NYSE: NVS) is building the case for its radioligand therapy, 177Lu-PSMA-617. With positive Phase 3 primary endpoint data in the bag, Novartis at the European Society of Medical Oncology Con...

6 days ago - Benzinga

Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with...

Basel, September 17, 2021 — Novartis today announced positive health-related quality of life (HRQoL) data from its Phase III VISION study evaluating 177Lu-PSMA-617, an investigational targeted radioliga...

1 week ago - GlobeNewsWire

A Look at R&D Spending in Pharma

In GAAP accounting, fixed assets are usually capitalized on a company's balance sheet and subsequently amortized over their expected useful life.

1 week ago - GuruFocus

3 International Stocks to Buy for Dividend Growth

International stocks tend to offer higher yields than their U.S.-based counterparts, and also offer geographic diversification. The post 3 International Stocks to Buy for Dividend Growth appeared first ...

Other symbols:DEOUL
2 weeks ago - InvestorPlace

Novartis Stops Iscalimab Trial In Kidney Transplant Patients

Novartis AG (NYSE: NVS) has halted a Phase 2 trial of CFZ533 (iscalimab) in kidney transplant patients. The decision follows interim data that showed iscalimab was not as good as tacrolimus-based treatm...

2 weeks ago - Benzinga

Novartis, NHS England Ink Access Deal For Cholesterol Drug Leqvio

The U.K. government, NHS England, and Novartis AG (NYSE: NVS) unveiled a "world-first" reimbursement deal for providing broader access to anti-cholesterol drug Leqvio (inclisiran) after the U.K.'s healt...

3 weeks ago - Benzinga

World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lower...

Basel, September 01, 2021 — Novartis has reached a commercial agreement with the NHS in England as part of a collaboration to pioneer a first-of-its-kind population health management approach to address...

3 weeks ago - GlobeNewsWire

Novartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other ke...

Basel, August 30, 2021 — Novartis will present new data from its robust portfolio and pipeline of advanced therapeutic platforms in solid tumors, with more than 55 abstracts from Novartis-sponsored and ...

3 weeks ago - GlobeNewsWire

Tonight! Novartis, Roche, BeiGene, Others Discuss Global Fight Against Cancer In Covid Era

Against that backdrop, Forbes China will hold the second “Forbes China Healthcare Summit” at 8pm ET tonight (8am on August 28 in China).

Other symbols:BGNE
3 weeks ago - Forbes

Lonza appoints Novartis executive as new Chief Financial Officer

Lonza has appointed former Novartis executive Philippe Deecke as its new Chief Financial Officer, the Swiss chemicals company said on Thursday.

4 weeks ago - Reuters

Novartis' STAMP Inhibitor Under FDA Review For Myeloid Leukemia

The FDA has accepted for review Novartis AG's (NYSE: NVS) marketing application seeking approval for asciminib (ABL001) in chronic myeloid leukemia (CML). Under Priority Review, the application is based...

4 weeks ago - Benzinga

Novartis (NVS) Kymriah Misses Primary Endpoint in NHL Study

Novartis' (NVS) phase III study evaluating Kymriah for second-line treatment of patients with aggressive B-cell NHL fails to achieve primary endpoint of the study.

4 weeks ago - Zacks Investment Research

Novartis's Kymriah Flunks In Late-Stage NHL Study

Novartis AG's (NYSE: NVS) Kymriah (tisagenlecleucel) CAR-T therapy failed to meet its primary endpoint of event-free survival in a Phase 3 study in aggressive B-cell non-Hodgkin lymphoma (NHL). The BELI...

4 weeks ago - Benzinga

Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Ho...

Basel, August 24, 2021 — Novartis today announced an update on the Phase III BELINDA study investigating Kymriah® (tisagenlecleucel) in aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack...

1 month ago - GlobeNewsWire

Novartis Shares Two Year Beovu Data From Diabetic Macular Edema Studies

Novartis AG (NYSE: NVS) has reported data from two Phase 3 trials assessing Beovu (brolucizumab) 6 mg versus Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Eylea (aflibercept) 2 mg in patients with diab...

1 month ago - Benzinga

Here Are the Winners of Cowen's Big Pharma R&D Showdown

The Wall Street firm put big drugmakers' R&D programs through five different tests.

1 month ago - The Motley Fool

Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN

Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.

1 month ago - Zacks Investment Research